LARGACTIL - PRO 25 mg/5 mL, a medication that belongs to the phenothiazine class (neuroleptic drugs). It is primarily used for the treatment of a wide range of neurological disorders affecting the central nervous system (CNS), as well as conditions affecting the gastrointestinal system. Additionally, it is used for the treatment of certain blood circulation-related disorders.

LARGACTIL - PRO is available in multiple pharmaceutical forms, including injectable ampoules for intramuscular and intravenous use, as well as F.C tablets.

Each 5 mL of LARGACTIL - PRO 25 mg/5 mL ampoules contain 25 mg Chlorpromazine HCl.

LARGACTIL - PRO 25 mg/5 mL is indicated for the treatment of emotional and mental disorders.

LARGACTIL - PRO 25 mg/5 mL is considered effective in treating psychotic conditions, such as agitation and irritability.

LARGACTIL - PRO 25 mg/5 mL is used to treat motor disturbances in schizophrenic patients.

LARGACTIL - PRO 25 mg/5 mL is prescribed for the treatment of the manic phase of bipolar depression.

LARGACTIL - PRO 25 mg/5 mL is indicated to control excessive motor activity, aggression, tension, and anxiety.

LARGACTIL - PRO 25 mg/5 mL may be used before surgical procedures to alleviate insomnia and fear.

LARGACTIL - PRO 25 mg/5 mL can be used to treat vomiting or nausea when other medications have failed.

In cases of intractable hiccups, LARGACTIL - PRO 25 mg/5 mL may be used.

LARGACTIL - PRO 25 mg/5 mL is prescribed for the treatment of acute intermittent porphyria.

Children:

The efficacy of LARGACTIL - PRO 25 mg/5 mL ampoules has not been established in children under 6 months of age.

Pregnancy& breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking LARGACTIL - PRO 25 mg/5 mL.

LARGACTIL - PRO 25 mg/5 mL crosses the placenta, and some studies have shown the possibility of fetal malformations.

Infants born to mothers who used LARGACTIL - PRO 25 mg/5 mL ampoules during the third trimester of pregnancy are at risk of experiencing postnatal withdrawal symptoms, extrapyramidal disorders, and respiratory distress.

Pregnancy Category: D.

LARGACTIL - PRO 25 mg/5 mL ampoules should not be used whilst breastfeeding because of small amounts of LARGACTIL - PRO 25 mg/5 mL appear in breast milk.

Adults:

Central Nervous System (CNS) Disorders:

The recommended dose of LARGACTIL - PRO 25 mg/5 ml ampoules is a single ampoule administered intramuscularly. A subsequent dose of 1-2 ampoules may be given after 1-4 hours if necessary.

For hospitalized patients, the recommended dose of LARGACTIL - PRO 25 mg/5 ml ampoules range from 1-3 ampoules daily. The dose can be gradually increased over several days up to 400 mg, administered 4 to 6 times daily in exceptionally severe cases, until the patient is stabilized.

Pre-surgical apprehension:

The recommended dose of LARGACTIL - PRO 25 mg/5 mL ampoules ranges from ½ to 1 ampoule, administered I.M.

Gastrointestinal Disorders:

Vomiting and Nausea: The recommended dose of LARGACTIL - PRO 25 mg/5 ml ampoules is 1-2 ampoules administered intramuscularly every 4-6 hours daily.

Vomiting and Nausea During Surgical Procedures:

(I.M.): The recommended dose of LARGACTIL - PRO 25 mg/5 ml ampoules is half an ampoule, administered intramuscularly. The dose can be repeated after 30 minutes if needed and in the absence of hypotension.

(I.V.): The recommended dose of Largactil-Pro 25 mg/5 mL ampoules is 2 mg every 2 minutes, ensuring the total dose does not exceed 25 mg/5 mL.

Intractable Hiccups (following the use of F.C tablets):

(I.M.): Administer 1-2 ampoules intramuscularly every 3-4 hours daily.

(I.V.): If symptoms persist, administer 1-2 ampoules via slow intravenous infusion with the patient lying flat in bed (blood pressure monitoring is required).

Bloodstream Disorders (acute intermittent porphyria):

The recommended dose of LARGACTIL - PRO 25 mg/5 ml ampoules is a single ampoule administered intramuscularly every 6-8 hours daily.

Children:

Central Nervous System (CNS) Disorders:

For managing hyperkinetic and aggressive states: The recommended dose of Largactil-Pro 25 mg/5 mL ampoules is 0.55 mg/kg, administered every 6 - 8 hours as needed.

Pre-surgical apprehension: The recommended dose of Largactil-Pro 25 mg/5 mL ampoules is 0.55 mg/kg, administrated I.M.

Gastrointestinal Disorders:

Vomiting and nausea: The recommended dose of Largactil-Pro 25 mg/5 mL ampoules is 0.55 mg/kg, administered every 6–8 hours as needed.

Vomiting and nausea during surgical procedures:

(I.M.): The recommended dose of Largactil-Pro 25 mg/5 mL ampoules is 0.275 mg/kg, which can be repeated after 30 minutes as needed and in the absence of hypotension.

(I.V.): The recommended dose of Largactil-Pro 25 mg/5 mL ampoules is 1 mg every 2 minutes.